Update on treatment strategies

International Review of Psychiatry

Volumn 9, Issue 4, 1997, Pages 419-428

  Kane, John M ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LITHIUM; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PROPRANOLOL; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TRIFLUOPERAZINE;

CLINICAL TRIAL; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; NEGATIVE SYNDROME; PARKINSONISM; PATIENT CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT OUTCOME; VOCATION;

EID: 0030691893     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540269775286     Document Type: Review

References (59)

1. ALVIR, J. M., LIEBERMAN, J. A., SAFFERMAN, A. Z., SCHWIMMER, J. L. & SCHAAF, J. A. (1993). Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New England Journal of Medicine, 329, 162-167.
2. BEASLEY, C. M., TOLLEFSON, G., TRAN, P., SADERLEY, W., SANGER, T., HAMILTON, S. & THE OLANZAPINE HGAD STUDY GROUP (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
3. BREIER, A., BUCHANAN, R. W., KIRKPATRICK, B., DAVIS, O. R., IRISH, D., SUMMERFELT A. & CARPENTER W. T. (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 51, 20-26.
4. CARPENTER W. T. JR, CONLEY, R. R., BUCHANAN, R. W. et al. (1995). Patient response and resource management: another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152, 827-832.
5. CARPENTER, W. T. JR, HANLON, T. E., HEINRICHS, D. W., KIRKPATRICK, B., LEVINE, J. & BUCHANAN, R. W. (1990). Continuous vs. targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry, 147, 1138-1148.
6. CHRISTISON, G. W., KIRCH, D. G. & WYATT, R. J. (1991). When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin, 17, 217-245.
7. CROW, T. J., MCMILLIAN, J. F., JOHNSON, A. L. & JOHNSTONE, E. C. (1986). A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120-127.
8. DAVIS, J. M. & CASPER, R. (1997). Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs, 14, 260-282.
9. DAVIS, J. M., METALON, L., WATANABE, M. D. & BLAKE, L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773.
10. ERICKSON, S. E., HURT, S. W., CHANG, S. & DAVIS, J. M. (1978). Haloperidol dose, plasma levels and clinical response, a double-blind study. Psychopharmacology Bulletin, 14, 15-16.
11. GAEBEL, W. & PIETZCKER, A. (1985). One-year-outcome of schizophrenic patients - the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry, 18, 235-239.
12. GILBERT, P. L., HARRIS, M. J., MCADAMS, L. A. & JESTE, D. V. (1995). Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry, 52, 173-188.
13. GLAZER, W. M. & KANE, J. M. (1992). Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry, 53(12), 426-433.
14. HERZ, M. I., GLAZER, W. M., MOSTERT, M. A., SHEARD, M. A., SZYMANSKI, H. V., HAFEZ, H., MIZRA, M. & VANA, J. (1991). Intermittent vs. maintenance medication in schizophrenia: two year results. Archives of General Psychiatry, 48, 333-339.
15. HERZ, M. I. & MELVILLE C. (1980). Relapse in schizophrenia. American Journal of Psychiatry, 37, 801-805.
16. HOGARTY, G. E., MCEVOY, J. P., MUNETZ, M., DIBARRY, A. L., BARTONE, P., CATHER, R., COOLEY, S. J., ULRICH, R. J., CARTER, M., MADONIA, M. J. & ENVIRONMENTAI/PERSONAL INDICATORS IN THE COURSE OF SCHIZOPHRENIA RESEARCH GROUP (1988). Dose of fluphenazine, familial expressed emotion and outcome in schizophrenia. Archives of General Psychiatry, 45, 797-805.
17. HONIGFELD, G. & PATIN, J. (1989). Predictors of response to clozapine therapy. Psychopharmacology, 99, S64-S67.
18. JANICAK, P. G., DAVIS, J. M., PRESKORN, S. H. & AYD, F. J. JR. (1993). Principals and practice of pharmacotherapy (pp. 104-106). Baltimore: Williams & Wilkins.
19. JOHNSON, D. A. W., LUDLOW, J. M., STREET, K. et al. (1987). Double-blind comparison of half-dose and standard flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. British Journal of Psychiatry, 151, 634-638.
20. JOLLEY, A. G., HIRSCH, S. R., MORRISON, E., MCRINK, A. & WILSON, L. (1990). Trial of brief intermittent prophylaxis for selected schizophrenia outpatients: clinical and social outcome at two years. British Medical Journal , 301, 837-842.
21. JOLLEY, A. G., HIRSCH, S. R., MCRINK, A. & MANCHANDA, R. (1989). Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. British Medical Journal, 298, 985-990.
22. KANE, J. M. (1994). Commentary on the clozapine conflict (letter). American Journal of Psychiatry, 153, 1507-1508.
23. KANE, J. M. & LIEBERMAN, J. A. (1987). Maintenance pharmacotherapy in schizophrenia. In: H. Y. MELTZER (Ed.), Psychopharmacology: the third generation of progress (pp. 1103-1109). New York: Raven Press.
24. KANE, J. M. & MCGLASHAN, T. H. (1995). Treatment of schizophrenia. Lancet, 346, 820-825.
25. KANE, J. M., DAVIS, J. M., SCHOOLER, N. R., MARDER, S. R., BRAUZER, B. & CASEY, D. E. (1993). A one-year comparison of four dosages of haloperidol decanoate. Schizophrenia Research, 9, 239-240.
26. KANE, J, HONIGFELD, G., SINGER, J. & MELTZER, H. (1988). Clozapine for the treatment-resistant schizophrenics: a double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry, 45, 789-796.
27. KANE, J. M., QUITKIN, F., RIFKIN, A., RAMOS-LORENZI, J. R. & NAYAK, D. V. (1982). Fluphenazine versus placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry, 39, 70-73.
28. KANE, J. M., RIFKIN, A., WOERNER, M. G. et al. (1983). Low-dose neuroleptic treatment of outpatient schizophrenics, I. Preliminary results for relapse rates. Archives of General Psychiatry, 40, 893-896.
29. KANE, J. M., SAFFERMAN, A. Z., POLLACK, S. et al. (1994). Clozapine, negative symptoms, and extrapyramidal side effects. Journal of Clinical Psychiatry, 55(suppl), 82-87.
30. KANE, J. M., SCHOOLER, N. & MARDER, S. (1996). A six-month comparison of clozapine and haloperidol. Presented at the 35th American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 9-13.
31. KANE, J. M., WOERNER, M. G. & SARANTAKOS, S. (1986). Depot neuroleptics: a comparative review of standard, intermediate and low-dose regimens. Journal of Clinical Psychiatry, 47(suppl), 30-33.
32. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry, 153, 948-950.
33. KINON, B. J., KANE, J. M., JOHNS, C. et al. (1993). Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacological Bulletin, 29(2), 309-314.
34. KLEIN, D. F. & DAVIS, J. (1968). Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams & Wilkins.
35. LIEBERMAN, J. A., SAFFERMAN, A. Z., POLLACK, S. et al. (1994). Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry, 151, 1744-1752.
36. MARDER, S. R., VAN PUTTEN, T., MINTZ, J., LEBELL, M., MCKENZIE, J. & MAY, P. R. (1987). Low and conventional dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Archives of General Psychiatry, 44, 518-521.
37. MARDER, S. R., VAN PUTTEN, T., MINTZ, J., MCKENZIE, J., LEBELL, M., FAUTICO, G. & MAY, P. R. A. (1984). Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry, 41, 1025-1029.
38. MAY, P. R. A. (1968). Treatment of schizophrenia. New York: Science House.
39. MCCREADIE, R. G. & MACDONALD, I. M. (1997). High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry, 131, 310-316.
40. MCEVOY, J. P., HOGARTY, G. E. & STEINGARD, S. (1991). Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 739-745.
41. MELTZER, H. Y. (1995). Clozapine: is another view valid? American Journal of Psychiatry, 52, 821-825.
42. NEBORSKY, R., JANOWSKY, D., MUNSON, E. & DEPRY, D. (1981). Rapid treatment of acute psychotic symptoms with high and low dose haloperidol. Archives of General Psychiatry 38, 195-199.
43. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry, 33, 227-235.
44. 2 receptor occupancy during low-dose treatment with haloperidol decanoate. American Journal of Psychiatry, 152, 173-178.
45. PICKAR, D., OWEN, R. R. JR, LITMAN, R. E. et al. (1994). Predictors of clozapine response in schizophrenia. Journal of Clinical Psychiatry, 55(suppl), 122-125.
46. PIETZCKER, A., GAEBEL, W., KOPCKE, W. et al. (1993). Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2 year results of a German multicenter study. Journal of Psychiatric Research, 27, 321-339.
47. QUITKIN, F., RIFKIN, A. & KLEIN, D. F. (1975). Very high dosage versus standard dosage fluphenazine in schizophrenia: a double-blind study of non-chronic treatment refractory patients. Archives of General Psychiatry, 32, 1276-1281.
48. RIFKIN, A., DODDI, S., KARAGI, B., BORENSTEIN, M. & WACHPRESS, M. (1991). Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166-170.
49. ROBINSON, D., LIEBERMAN, J., SHEITMAN, B., ALVIR, J. M. A. & KANE, J. (1996). Pilot study of atypical antipsychotic agents in first episode schizophrenia. Poster presentation American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 9-13.
50. SALZMAN, C. (1980). The use of ECT in the treatment of schizophrenia. American Journal of Psychiatry, 137, 1032-1041.
51. SALZMAN, C., SOLOMON, D., MIYAWAKI, E. et al. (1991). Parenteral lorazapam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry, 52, 177-180.
52. SCHOOLER, N. R., KEITH, S. J., SEVERE, J. B. et al. (1997). Relapse and rehospitalization during maintenance phase treatment of schizophrenia: the effects of dose reduction and family treatment. Archives of General Psychiatry, 54, 453-463.
53. SCHULZ, S. C., ODBERT, C., THOMPSON, P. et al. (1993). Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic patients. Paper presented at the New Clinical Drug Evaluation Unit annual meeting, Florida.
54. SHALEV, A., HERMESH, H., ROTHBERG, J. & MUNITZ, H. (1993). Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavia, 87, 86-91.
55. SHEPHERD, M., WATT, D., FALLOON, I. & SMEETON, N. (1989). The natural history of schizophrenia, a five year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine Monograph (supp. 15). Cambridge: Cambridge University Press.
56. SMALL, J. G., KELLAMS, J. J., MILSTEIN, V. & MOORE, J. (1975). A placebo controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry, 132, 1315-1317.
57. VAN PUTTEN, T., MARDER, S. R., WIRSHING, W. C., ARAVAGIRI, M. & CHABERT, N. (1991). Neuroleptic plasma levels. Schizophrenia Bulletin, 17, 197-216.
58. WOLKIN, A., BAROUCHE, F., WOLF, A. P. et al. (1989). Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry, 146, 905-908.
59. ZIMBROFF, D. L., KANE, J. M., TAMMINGA, C. A., DANIEL, D. G., MACK, R. J., MORRIS, D. D., SEBREE, T. B., WALLIN, B. A., KASHKIN, K. B. & THE SERTINDOLE STUDY GROUP (1997). A controlled, dose-response study of sertindole and haloperidol in schizophrenia. American Journal of Psychiatry, 1154, 782-791.